No headlines found.
RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
Globe Newswire (Sun, 26-Jul 4:00 PM ET)
Globe Newswire (Wed, 15-Jul 4:15 PM ET)
Business Wire (Fri, 10-Jul 1:55 PM ET)
Business Wire (Wed, 8-Jul 12:00 PM ET)
Business Wire (Tue, 7-Jul 3:05 PM ET)
Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs
Business Wire (Mon, 6-Jul 4:15 PM ET)
Globe Newswire (Mon, 6-Jul 4:15 PM ET)
Did RxSight, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
PRNewswire (Thu, 2-Jul 3:02 PM ET)
RxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology Forum
Globe Newswire (Tue, 19-May 4:10 PM ET)
RxSight, Inc. Reports First Quarter 2026 Results and Reiterates Full-Year Sales Outlook
Globe Newswire (Wed, 6-May 4:05 PM ET)
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.
Rxsight trades on the NASDAQ stock market under the symbol RXST.
As of August 3, 2026, RXST stock price climbed to $6.29 with 703,446 million shares trading.
RXST has a beta of 0.75, meaning it tends to be less sensitive to market movements. RXST has a correlation of 0.02 to the broad based SPY ETF.
RXST has a market cap of $260.38 million. This is considered a Small Cap stock.
Last quarter Rxsight reported $31 million in Revenue and -$.19 earnings per share. This beat revenue expectation by $1 million and missed earnings estimates by -$.03.
In the last 3 years, RXST traded as high as $66.54 and as low as $4.48.
The top ETF exchange traded funds that RXST belongs to (by Net Assets): IWM, VTI, IWN, VXF, VTWO.
RXST has underperformed the market in the last year with a return of -19.2%, while the SPY ETF gained +21.1%. In the last 3 month period, RXST fell short of the market, returning -11.0%, while SPY returned +5.7%. However, in the most recent 2 weeks RXST has outperformed the stock market by returning +13.3%, while SPY returned +1.9%.
RXST support price is $5.71 and resistance is $6.32 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RXST shares will trade within this expected range on the day.